GL

Globe Life Inc

Add to Watchlist

Advanced Chart

142.830

-0.44(-0.307%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

143.000

Open

142.600

VWAP

Vol

53.84K

Mkt Cap

11.83B

Low

142.120

Amount

EV/EBITDA(TTM)

9.72

Total Shares

92.27M

14.40B

EV/OCF(TTM)

P/S(TTM)

2.07

Globe Life Inc. is an insurance holding company. Its primary subsidiaries are Globe Life And Accident Insurance Company, American Income Life Insurance Company, Liberty National Life Insurance Company, Family Heritage Life Insurance Company of America, and United American Insurance Company. The Company’s segments include life insurance, supplemental health insurance, and investments. Life insurance products include traditional whole life and term life insurance. The Company offers Medicare Supplement and limited-benefit supplemental health insurance products that include accident, cancer, critical illness, heart, intensive care, and other health products. These products are designed to supplement health coverage that applicants already own. Medicare Supplements are offered to enrollees in the traditional fee-for-service Medicare program. Medicare Supplement plans are standardized by federal regulation and are designed to pay deductibles and co-payments not paid by Medicare.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

1.56B

+5.18%

3.515

+14.5%

1.53B

+4.5%

3.540

+12.74%

1.52B

+4.22%

4.172

+19.54%

Estimates Revision

The market is revising Upward the revenue expectations for Globe Life Inc. (GL) for FY2025, with the revenue forecasts being adjusted by 0.09% over the past three months. During the same period, the stock price has changed by 15.80%.

Revenue Estimates for FY2025

Revise Upward

+0.09%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+15.80%

In Past 3 Month

10 Analyst Rating

-0.30% Downside

Wall Street analysts forecast GL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GL is 142.40 USD with a low forecast of 118.00 USD and a high forecast of 168.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

3 Hold

0 Sell

Moderate Buy

-0.30% Downside

Current: 142.830

Low

118.00

Averages

142.40

High

168.00

-0.30% Downside

Current: 142.830

Low

118.00

Averages

142.40

High

168.00

Keefe Bruyette

Outperform

maintain

$155 -> $165

2025-07-29

New

Reason

Keefe Bruyette

Price Target

$155 -> $165

2025-07-29

New

maintain

Outperform

Reason

Keefe Bruyette raised the firm's price target on Globe Life to $165 from $155 and keeps an Outperform rating on the shares after the company announced the Department of Justice closed its investigation into its sales practices with no enforcement action. The firm says the news ends the risk that began for Globe Life in April 2024. Keefe cites the company's history of growing premiums and earnings for the target bump.

Keefe Bruyette

Outperform

maintain

$155 -> $160

2025-07-29

New

Reason

Keefe Bruyette

Price Target

$155 -> $160

2025-07-29

New

maintain

Outperform

Reason

Keefe Bruyette raised the firm's price target on Globe Life to $160 from $155 and keeps an Outperform rating on the shares after the company announced the Department of Justice closed its investigation into its sales practices with no enforcement action. The firm says the news ends the risk that began for Globe Life in April 2024. Keefe cites the company's history of growing premiums and earnings for the target bump.

Keefe Bruyette

Outperform

maintain

$145 -> $155

2025-07-28

New

Reason

Keefe Bruyette

Price Target

$145 -> $155

2025-07-28

New

maintain

Outperform

Reason

Keefe Bruyette raised the firm's price target on Globe Life to $155 from $145 and keeps an Outperform rating on the shares.

Morgan Stanley

Bob Huang

Equal Weight

maintain

$127 -> $135

2025-07-25

New

Reason

Morgan Stanley

Bob Huang

Price Target

$127 -> $135

2025-07-25

New

maintain

Equal Weight

Reason

Morgan Stanley analyst Bob Huang raised the firm's price target on Globe Life to $135 from $127 and keeps an Equal Weight rating on the shares. With "marginally better than expected" earnings and a large share price move, some investors asked how durable is the post results share price appreciation, notes the analyst, who views the share price rebound as "justified." However, the firm believes the company needs further clarity from the DOJ probe for the stock to see additional upside, the analyst added.

Truist

Buy

initiated

$150

2025-07-15

Reason

Truist

Price Target

$150

2025-07-15

initiated

Buy

Reason

Truist initiated coverage of Globe Life with a Buy rating and $150 price target. The firm says the company's diversified model that supports steady returns while the shares trade at a discount to peers. The stock can now be bought at a discount valuation because of a "misguided" short report and short-term volatility in medical utilization, the analyst tells investors in a research note.

Morgan Stanley

Bob Huang

Equal Weight

maintain

$125 -> $127

2025-07-14

Reason

Morgan Stanley

Bob Huang

Price Target

$125 -> $127

2025-07-14

maintain

Equal Weight

Reason

Morgan Stanley analyst Bob Huang raised the firm's price target on Globe Life to $127 from $125 and keeps an Equal Weight rating on the shares.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Globe Life Inc (GL.N) is 9.17, compared to its 5-year average forward P/E of 10.72. For a more detailed relative valuation and DCF analysis to assess Globe Life Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

10.72

Current PE

9.17

Overvalued PE

12.63

Undervalued PE

8.80

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

9.63

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

11.20

Undervalued EV/EBITDA

8.05

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1.82

Current PS

0.00

Overvalued PS

2.05

Undervalued PS

1.59